Lung Forum 2025-2026
Accreditation Information
Target Audience
The target audience for this activity is medical oncology, radiation oncology, thoracic oncology, and thoracic surgical fellows and junior faculty actively involved in clinical research for patients with thoracic oncology.
Learning Objectives
- Assess the safety and efficacy of current and emerging therapeutic approaches for the treatment of patients with lung cancer, including modalities such as traditional chemotherapy, radiotherapy, surgery, molecularly targeted agents, immunotherapy, and others
- Develop strategies to foster participation in clinical trials from both clinicians and patients with lung cancer in order to introduce novel agents into practice that improve the outcomes of patients with these malignancies
- Evaluate techniques to enhance communication and collaboration among multidisciplinary healthcare teams in order to optimize and improve patient outcomes
- Compare and contrast strategies for the professional development of thoracic oncology fellows and junior faculty into leadership positions in oncology research and care of patients with lung cancer
Accreditation
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Bio Ascend. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this live activity for a maximum of 10.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
2025 Next Wave Faculty/Investigator Disclosures
Julie R. Brahmer, MD, MSc – Co-Chair
Consultant/Advisor/Speaker: Amgen, AstraZeneca, Bristol Myers Squibb, GSK, Janssen/Johnson & Johnson, RAPT Therapeutics, Summit Therapeutics
Researcher: AstraZeneca
Suresh Ramalingam, MD, FACP, FASCO – Co-Chair
Grant or Research Support for Institution: AstraZeneca, Amgen, Pfizer, Bristol Myers Squibb,
Participation on a Data Safety Monitoring Board or Advisory Board (No payments): Gilead, Johnson & Johnson
Jeffrey Bradley, MD, FASTRO, FACR
Consultant/Advisor/Speaker: AstraZeneca, Inc., Genentech, Inc., IBA Inc., Mevion Medical Systems, Inc.
Shirish Gadgeel, MD
Consultant/Advisor/Speaker: AbbVie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Genentech/Roche, Gilead, Johnson & Johnson, Novartis, Nuvation, Pfizer, Takeda
Researcher: Daiichi Sankyo, Genentech/Roche, Nuvalent, Pfizer
Ramaswamy Govindan, MD
No relevant financial relationships to disclose
Onkar Khullar, MD, MSc
Consultant/Advisor/Speaker: Merck, Roche
Mark Kris, MD
Consultant/Advisor/Speaker: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Merus, Mirati Therapeutics, Pfizer, Sanofi
Other: Merck
Ticiana Leal, MD
Consultant/Advisor/Speaker: AbbVie, Amgen, AstraZeneca, Black Diamond Therapeutics, Bristol Myers Squibb, Boehringer Ingelheim, Catalyst, Genentech, Gilead, Jazz, J&J, Novartis, Novocure, OncoC4, Pfizer, Regeneron, Roche, Sanofi, Synthekine, Takeda
Taofeek Owonikoko, MD, PhD
Advisory Board: Amgen; AstraZeneca; Bayer; BeiGene, Bella Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Coherus Biosciences, Daiichi Sankyo, Eisai, EMD Serono, GenCART, Genentech, Gilead, GSK, Heat Biologics, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Meryx, Novartis; Oncocyte, OncoHost, Puma Biosciences, Regeneron, Roche/Genentech, Inc., Takeda
Research Funding to Institution: Amgen Inc., AstraZeneca, Bayer Corporation, Bristol Myers Squibb, Cardiff Oncology, Inc., Eisai Inc., Roche/Genentech, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Oncorus, Inc., Pfizer, Turning Point Therapeutics, Inc., Y-mAbs Therapeutics, Inc, Daiichi Sankyo, Puma Biosciences, Cyclacel, GSK, Boehringer Ingelheim
Stock/Ownership: Coherus Biosciences, GenCART, Cambium Oncology, Taobob LLC
Rachel Sanborn, MD
Consultant/Advisor/Speaker: AstraZeneca, Amgen, Daiichi Sankyo, GE HealthCare, Gilead, Janssen Oncology/Johnson & Johnson, Lilly Oncology, Sanofi Aventis
Honoraria: Illumina
Gary L. Teal, MBA
No relevant financial relationships to disclose
Investigators
Anju Abhyankar, MBBS
No relevant financial relationships to disclose
Omar Abughanimeh, MBBS
No relevant financial relationships to disclose
Jacqueline Aredo, MD, MS
Consultant/Advisor/Speaker: AstraZeneca, Johnson & Johnson, Kaplan
Wint Yan Aung, MD, MPH
No relevant financial relationships to disclose
Benjamin Bleiberg, MD, MS
Consultant/Advisor/Speaker: Janssen Oncology
Other: MJH Life Sciences
Simone Dekker, MD, PhD
No relevant financial relationships to disclose
Waqas Haque, MD, MPH, MPhil
No relevant financial relationships to disclose
Robert Hsu, MD, MSc
Consultant/Advisor/Speaker: EMD Serono, MJH Life Sciences, Takeda, The Dendham Group
Other: Dava Oncology, Oncohost
Chinmay Jani, MBBS
No relevant financial relationships to disclose
Hyein Jeon, MD
No relevant financial relationships to disclose
Anam Kamal, MD
No relevant financial relationships to disclose
So Yeon Kim, MD
Researcher: AstraZeneca, Bioinvent, Boehringer Ingelheim, BridgeBio, Dynamicure, Genentech, Genmab, Gilead, LoxoLilly, Mirati/BMS, Monetrosa, Seagen, Takeda, Vaccibody
Consultant/Advisor/Speaker: Revolution Medicine
Jonathan Lee, MD
No relevant financial relationships to disclose
Abner Murray, MD, PhD
No relevant financial relationships to disclose
Tamar Nobel, MD, MPH
No relevant financial relationships to disclose
Kelsey Pan, MD, MPH
Consultant/Advisor/Speaker: Johnson & Johnson
Sadiq Rehmani, MBBS
No relevant financial relationships to disclose
Dena Rhinehart, MD, MS
No relevant financial relationships to disclose
Sarah Waliany, MD, MS
No relevant financial relationships to disclose
Shuai Wang, MD, MS
No relevant financial relationships to disclose
Leah Wells, MD
Other: AbbVie
Instructions for Credit
To receive CE credit, learners must follow these steps:
- Visit https://cme.partnersed.com/NextWaveLung2025
- Complete the activity evaluation
- Upon completion of all evaluation questions, your credit will be made available for download immediately.